FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

GOODMAN JONATHAN R.		 2. Issuer Name and Ticker or Trading Symbol

POINT Biopharma Global Inc. [ PNT ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

4850 WEST 78TH STREET		 3. Date of Earliest Transaction (MM/DD/YYYY)

6/30/2021
(Street)

INDIANAPOLIS, IN 46268
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

6/30/2021 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 6/30/2021  A  35872 A (1)35872 (2)I Long Zone Holdings Inc. (3)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) On June 30, 2021, POINT BIOPHARMA GLOBAL INC. (f/k/a Therapeutics Acquisition Corp., the "Issuer") consummated a business combination (the "Business Combination") pursuant to which Bodhi Merger Sub, Inc., a wholly-owned subsidiary of the Issuer, merged with and into POINT Biopharma Inc. ("Old POINT"). At the effective time of the Business Combination, each share of Old POINT outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an implied Old POINT vested equity value of $585,000,000. As a result, the Reporting Person received the reported shares of the Issuer's Common Stock in consideration for the equity securities of Old POINT held by the Reporting Person prior to the Business Combination.
(2) This amendment is being filed to correct an administrative error in a Form 4 filed by the Reporting Person on June 30, 2021, which incorrectly reported 21,523 shares of Common Stock as beneficially owned by the Reporting Person directly. This amendment reflects the correct number of shares of Common Stock beneficially owned by the Reporting Person as of June 30, 2021.
(3) A corporation controlled by Reporting Person
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
GOODMAN JONATHAN R.
4850 WEST 78TH STREET
INDIANAPOLIS, IN 46268		X
Signatures
William L. Demers, by Power of Attorney for Jonathan R. Goodman2/8/2022
**Signature of Reporting PersonDate
Therapeutics Acquisition (NASDAQ:RACA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Therapeutics Acquisition.
Therapeutics Acquisition (NASDAQ:RACA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Therapeutics Acquisition.